Spartalizumab is under clinical development by Novartis and currently in Phase I for Chronic Myelomonocytic Leukemia (CMML). According to GlobalData, Phase I drugs for Chronic Myelomonocytic Leukemia (CMML) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Spartalizumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Spartalizumab overview
Spartalizumab (PDR-001) is under development for the treatment of clear cell renal cell carcinoma, advanced solid tumors including malignant melanoma, non small cell lung cancer (NSCLC), metastatic squamous cell anal carcinoma, hepatocellular carcinoma, ocular melanoma, triple negative breast cancer, renal cell cancer, anaplastic thyroid cancer, recurrent or metastatic nasopharyngeal carcinoma, metastatic microsatellite stable colorectal cancer, esophageal squamous cell carcinoma, recurrent head and neck cancer squamous cell carcinoma, endometrial cancer, recurrent glioblastoma, advanced pancreatic cancer, relapsed and refractory multiple myeloma, metastatic ovarian cancer, de novo, myelodysplastic syndrome, relapsed and refractory acute myeloid leukemia. The monoclonal antibody is administered as intravenous infusion and is directed against programmed death 1 protein (PD-1). It is a humanized anti-programmed death-1 (PD-1) IgG4 antibody. It was also under development for neuroendocrine gastroenteropancreatic tumors (gep-net) and neuroendocrine tumors. It is a new molecular entity (NME).
It was under development for diffuse large B-cell lymphoma, gastrointestinal stromal tumor, Hodgkin's lymphoma, BRAF V600 mutation-positive cutaneous melanoma and locoregional solid malignancies.
Novartis overview
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. Novartis conducts research in various disease areas through the BioMedical Research division. The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
For a complete picture of Spartalizumab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
